Joelle Wiels

Villejuif, 94805, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

The pro-apoptotic peptide PEP-010 triggers apoptosis in pancreatic tumor models in monotherapy and in combination with gemcitabine independently of the KRAS status.

The pro-apoptotic peptide PEP-010 triggers apoptosis in pancreatic tumor models in monotherapy and in combination with gemcitabine independently of the KRAS status.

Journal: Cancer letters

Published: January 28, 2025

The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models.

The first-in-class pro-apoptotic peptide PEP-010 is effective in monotherapy and in combination with paclitaxel on resistant ovarian adenocarcinoma cell models.

Journal: Frontiers in pharmacology

Published: June 06, 2024

A translational study for biomarker identification of PEP-010, a pro-apoptotic peptide restoring apoptosis in cancer models.

A translational study for biomarker identification of PEP-010, a pro-apoptotic peptide restoring apoptosis in cancer models.

Journal: Biochimica et biophysica acta. Molecular basis of disease

Published: March 18, 2024

Epstein-Barr virus reactivation induces MYC-IGH spatial proximity and t(8;14) in B cells.

Epstein-Barr virus reactivation induces MYC-IGH spatial proximity and t(8;14) in B cells.

Journal: Journal of medical virology

Published: August 04, 2022

In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration.

In vitro evaluation of NA1-115-7-loaded nanoemulsions, an MCL-1-specific inhibitor of natural origin, intended to treat B-cell lymphoproliferative disorders after oral administration.

Journal: International journal of pharmaceutics

Published: July 18, 2022

NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.

NA1-115-7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: June 16, 2022

Shiga Toxins as Antitumor Tools.

Shiga Toxins as Antitumor Tools.

Journal: Toxins

Published: August 17, 2021

Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.

Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL-1.

Journal: ChemMedChem

Published: January 07, 2021

Oncogenic Properties of the EBV ZEBRA Protein.

Oncogenic Properties of the EBV ZEBRA Protein.

Journal: Cancers

Published: May 19, 2020

The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.

The BCL-2 family protein inhibitor ABT-737 as an additional tool for the treatment of EBV-associated post-transplant lymphoproliferative disorders.

Journal: Molecular oncology

Published: April 27, 2020

Verotoxin-1-Induced ER Stress Triggers Apoptotic or Survival Pathways in Burkitt Lymphoma Cells.

Verotoxin-1-Induced ER Stress Triggers Apoptotic or Survival Pathways in Burkitt Lymphoma Cells.

Journal: Toxins

Published: April 10, 2020

Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.

Correction: Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.

Journal: Leukemia

Published: November 24, 2019

Showing 1-12 of 28

Last Updated: 09/26/2026